Masitinib -- targeted therapy for cancers, inflammatory diseases and neurological indications
Wednesday, September 30, 2009 - 07:14
in Health & Medicine
In new research published in the open-access, peer-reviewed scientific journal PLoS ONE, Dr Patrice Dubreuil and colleagues characterise the pharmacological profile of masitinib (AB1010), a novel tyrosine kinase inhibitor (TKI) that targets the stem cell factor (KIT), PDGFR and Lyn.